Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility

Item

http://www.wikidata.org/entity/Q35941273

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Effect of natural polymorphism ...... inhibitor hypersusceptibility

@ast

Effect of natural polymorphism ...... inhibitor hypersusceptibility

@en

type

Item

label

Effect of natural polymorphism ...... inhibitor hypersusceptibility

@ast

Effect of natural polymorphism ...... inhibitor hypersusceptibility

@en

prefLabel

Effect of natural polymorphism ...... inhibitor hypersusceptibility

@ast

Effect of natural polymorphism ...... inhibitor hypersusceptibility

@en

P1476

Effect of natural polymorphism ...... inhibitor hypersusceptibility

@en

P2093

André F A Santos

http://www.w3.org/2001/XMLSchema#string

Annette Ratcliff

http://www.w3.org/2001/XMLSchema#string

Denis M Tebit

http://www.w3.org/2001/XMLSchema#string

Eric J Arts

http://www.w3.org/2001/XMLSchema#string

Marcelo A Soares

http://www.w3.org/2001/XMLSchema#string

Matthew S Lalonde

http://www.w3.org/2001/XMLSchema#string

Ricardo S Diaz

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration

Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development

A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir

Differential drug resistance acquisition in HIV-1 of subtypes B and C

Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

Global trends in molecular epidemiology of HIV-1 during 2000-2007.

Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.

Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones

Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil.

P304

2719-2725

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.06079-11

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ricardo Camacho

Ana B. Abecasis

Ottmar Herchenröder

P577

2012-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22330918

http://www.w3.org/2001/XMLSchema#string

P932

3346603

http://www.w3.org/2001/XMLSchema#string